Hepatocyte‐derived EVs fuse directly with target hepatocytes and transfer neutral ceramidase and sphingosine kinase 2 (SK2), increasing the synthesis of sphingosine‐1‐phosphate (S1P) in target hepatocytes, thereby mediating liver repair and regeneration.[113] Furthermore, intravenously injected EVs show prominent accumulation in the liver and a reduction in rapid renal clearance, making them an appropriate treatment for liver diseases. The gene discussed is SPHK2; the disease is liver disorder.